Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-10

AUTHORS

N. Wei, B. Zhang, Y. Wang, X. H. He, L. C. Xu, G. D. Li, Y. H. Wang, G. Z. Wang, H. Z. Huang, W. T. Li

ABSTRACT

PurposeTo evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM).MethodsWe conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group). The objective response rate (ORR), disease control rate (DCR), overall survival (OS, from the first TACE), progression-free survival (PFS, from the first TACE), and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed.ResultsThe ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively (P = 0.076), and the DCRs were 86.9 and 80.0%, respectively (P = 0.452). The median OS (from first TACE) was 14.0 months in the raltitrexed group and 13.0 months in the FUDR group (P = 0.556). The median PFS (from first TACE) was 2.1 months in the raltitrexed group and 2.4 months in the FUDR group (P = 0.878). Univariate and multivariate analyses showed that the primary tumor site, Child–Pugh class, and combination with local ablation (RFA or CRA) were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups (P > 0.05), and no treatment-related death occurred in either group.ConclusionTACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM. More... »

PAGES

443-450

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12094-018-1942-0

DOI

http://dx.doi.org/10.1007/s12094-018-1942-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107535568

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30306400


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoembolization, Therapeutic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Floxuridine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiophenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Medical, Peoples Hospital Xintai City, Taishan Medical University, 271200, Xintai, China", 
          "id": "http://www.grid.ac/institutes/grid.410638.8", 
          "name": [
            "Department of Interventional Medical, Peoples Hospital Xintai City, Taishan Medical University, 271200, Xintai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "He", 
        "givenName": "X. H.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "L. C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "G. D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Y. H.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "G. Z.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "H. Z.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "W. T.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-014-2585-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015600148", 
          "https://doi.org/10.1007/s00280-014-2585-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1994.68", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027895860", 
          "https://doi.org/10.1038/bjc.1994.68"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/mo:21:1:59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042837122", 
          "https://doi.org/10.1385/mo:21:1:59"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12094-012-0843-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029696709", 
          "https://doi.org/10.1007/s12094-012-0843-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00423-015-1308-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020499797", 
          "https://doi.org/10.1007/s00423-015-1308-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-008-0043-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013503650", 
          "https://doi.org/10.1245/s10434-008-0043-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602860", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018854110", 
          "https://doi.org/10.1038/sj.bjc.6602860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-82635-1_30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009009928", 
          "https://doi.org/10.1007/978-3-642-82635-1_30"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-10", 
    "datePublishedReg": "2018-10-10", 
    "description": "PurposeTo evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM).MethodsWe conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group). The objective response rate (ORR), disease control rate (DCR), overall survival (OS, from the first TACE), progression-free survival (PFS, from the first TACE), and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed.ResultsThe ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively (P\u2009=\u20090.076), and the DCRs were 86.9 and 80.0%, respectively (P\u2009=\u20090.452). The median OS (from first TACE) was 14.0\u00a0months in the raltitrexed group and 13.0\u00a0months in the FUDR group (P\u2009=\u20090.556). The median PFS (from first TACE) was 2.1\u00a0months in the raltitrexed group and 2.4\u00a0months in the FUDR group (P\u2009=\u20090.878). Univariate and multivariate analyses showed that the primary tumor site, Child\u2013Pugh class, and combination with local ablation (RFA or CRA) were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups (P\u2009>\u20090.05), and no treatment-related death occurred in either group.ConclusionTACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12094-018-1942-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1035367", 
        "issn": [
          "1699-048X", 
          "1699-3055"
        ], 
        "name": "Clinical and Translational Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "colorectal cancer liver metastases", 
      "unresectable colorectal cancer liver metastases", 
      "objective response rate", 
      "disease control rate", 
      "cancer liver metastases", 
      "transarterial chemoembolization", 
      "raltitrexed group", 
      "FUDR group", 
      "liver metastases", 
      "adverse reactions", 
      "treatment-related deaths", 
      "progression-free survival", 
      "Child-Pugh class", 
      "safe alternative choice", 
      "primary tumor site", 
      "independent significant factors", 
      "median PFS", 
      "systemic chemotherapy", 
      "median OS", 
      "overall survival", 
      "prognostic factors", 
      "control rate", 
      "retrospective analysis", 
      "local ablation", 
      "response rate", 
      "tumor site", 
      "multivariate analysis", 
      "patients", 
      "months", 
      "chemoembolization", 
      "chemotherapy", 
      "significant differences", 
      "survival", 
      "metastasis", 
      "oxaliplatin", 
      "raltitrexed", 
      "pirarubicin", 
      "FUDR", 
      "group", 
      "significant factor", 
      "MethodsWe", 
      "PFS", 
      "floxuridine", 
      "OS", 
      "PurposeTo", 
      "death", 
      "factors", 
      "treatment", 
      "alternative choice", 
      "ablation", 
      "rate", 
      "Department", 
      "safety", 
      "differences", 
      "analysis", 
      "combination", 
      "reaction", 
      "sites", 
      "choice", 
      "class", 
      "efficiency", 
      "ConclusionTACE treatment", 
      "floxuridine-based chemotherapy"
    ], 
    "name": "Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis", 
    "pagination": "443-450", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107535568"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12094-018-1942-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30306400"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12094-018-1942-0", 
      "https://app.dimensions.ai/details/publication/pub.1107535568"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_793.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12094-018-1942-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1942-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1942-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1942-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1942-0'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      22 PREDICATES      113 URIs      97 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12094-018-1942-0 schema:about N0d7a8415cbed44d7a6204cfd96af82c2
2 N1ed47606a3b94d719cfd311139715781
3 N2ff012c3c48346578de8f4762aa8a8c6
4 N418837322ed543f48e693ab1aabb3ff8
5 N5a8ca6c4437e447b813b6fbfcf784011
6 N67c53674987f4a669271b7f298e68928
7 N6fcd41767e334c709771dd311a117a48
8 N7cda6460b00b4beca8314c4ceed9fe50
9 N95c22bf5961d4398b36a8a5ca4a9835e
10 Na6555e985d17476fb0dec552013e9b79
11 Nae7d67e0464e4a6cb62b36de9c83984e
12 Nc248c2b9b0a84338b3b1c2f8154d9082
13 Ne13faefb94d5494c8c6f84db06068af9
14 Ne85b40a9a17c4084a3f0fb9d7b2488e9
15 Nf5721267517e4e17bfa59c5929974462
16 Nfde4c1ca94de437ba92fef9936233839
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N416465ef1ee0481e8294659de96def33
20 schema:citation sg:pub.10.1007/978-3-642-82635-1_30
21 sg:pub.10.1007/s00280-014-2585-7
22 sg:pub.10.1007/s00423-015-1308-9
23 sg:pub.10.1007/s12094-012-0843-x
24 sg:pub.10.1038/bjc.1994.68
25 sg:pub.10.1038/sj.bjc.6602860
26 sg:pub.10.1245/s10434-008-0043-7
27 sg:pub.10.1385/mo:21:1:59
28 schema:datePublished 2018-10-10
29 schema:datePublishedReg 2018-10-10
30 schema:description PurposeTo evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM).MethodsWe conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group). The objective response rate (ORR), disease control rate (DCR), overall survival (OS, from the first TACE), progression-free survival (PFS, from the first TACE), and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed.ResultsThe ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively (P = 0.076), and the DCRs were 86.9 and 80.0%, respectively (P = 0.452). The median OS (from first TACE) was 14.0 months in the raltitrexed group and 13.0 months in the FUDR group (P = 0.556). The median PFS (from first TACE) was 2.1 months in the raltitrexed group and 2.4 months in the FUDR group (P = 0.878). Univariate and multivariate analyses showed that the primary tumor site, Child–Pugh class, and combination with local ablation (RFA or CRA) were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups (P > 0.05), and no treatment-related death occurred in either group.ConclusionTACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM.
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N7c00322ce07b46f88e186dc4f828c642
35 Ncf32596edbc449d0accf009fd4aaee2c
36 sg:journal.1035367
37 schema:keywords Child-Pugh class
38 ConclusionTACE treatment
39 Department
40 FUDR
41 FUDR group
42 MethodsWe
43 OS
44 PFS
45 PurposeTo
46 ablation
47 adverse reactions
48 alternative choice
49 analysis
50 cancer liver metastases
51 chemoembolization
52 chemotherapy
53 choice
54 class
55 colorectal cancer liver metastases
56 combination
57 control rate
58 death
59 differences
60 disease control rate
61 efficiency
62 factors
63 floxuridine
64 floxuridine-based chemotherapy
65 group
66 independent significant factors
67 liver metastases
68 local ablation
69 median OS
70 median PFS
71 metastasis
72 months
73 multivariate analysis
74 objective response rate
75 overall survival
76 oxaliplatin
77 patients
78 pirarubicin
79 primary tumor site
80 prognostic factors
81 progression-free survival
82 raltitrexed
83 raltitrexed group
84 rate
85 reaction
86 response rate
87 retrospective analysis
88 safe alternative choice
89 safety
90 significant differences
91 significant factor
92 sites
93 survival
94 systemic chemotherapy
95 transarterial chemoembolization
96 treatment
97 treatment-related deaths
98 tumor site
99 unresectable colorectal cancer liver metastases
100 schema:name Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis
101 schema:pagination 443-450
102 schema:productId N1c584b7e8172421c9803c1f2a25e96d4
103 N9944d0063ac94db291733941ba925373
104 Nb5ffa7e875864bcabb46fe365baae1b5
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107535568
106 https://doi.org/10.1007/s12094-018-1942-0
107 schema:sdDatePublished 2021-11-01T18:33
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N29f1b89c0d3e470a9e41e100017a41fd
110 schema:url https://doi.org/10.1007/s12094-018-1942-0
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N050760c404aa41cb88386514ef8c1be8 schema:affiliation grid-institutes:grid.452404.3
115 schema:familyName Huang
116 schema:givenName H. Z.
117 rdf:type schema:Person
118 N0d7a8415cbed44d7a6204cfd96af82c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Male
120 rdf:type schema:DefinedTerm
121 N127a085f86134935a8eee6bd33aed6da schema:affiliation grid-institutes:grid.452404.3
122 schema:familyName Li
123 schema:givenName W. T.
124 rdf:type schema:Person
125 N1c584b7e8172421c9803c1f2a25e96d4 schema:name dimensions_id
126 schema:value pub.1107535568
127 rdf:type schema:PropertyValue
128 N1ed47606a3b94d719cfd311139715781 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Chemoembolization, Therapeutic
130 rdf:type schema:DefinedTerm
131 N26fa7b97ac894aad83dc7d4dc72990a7 rdf:first N9a6c1927454a46c497690bf003b1b311
132 rdf:rest Nbfd9d1feac3c465e9b9c3eacf9ded196
133 N29f1b89c0d3e470a9e41e100017a41fd schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 N2ff012c3c48346578de8f4762aa8a8c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Floxuridine
137 rdf:type schema:DefinedTerm
138 N3a306ec29eba4f0b81b2fbfa473603f5 rdf:first N763cfcc8c38c42228521963148f5d385
139 rdf:rest Nd53461c0b7d44e63862e578668981113
140 N3c58b7df38df49579afb88176d4ee8b5 schema:affiliation grid-institutes:grid.452404.3
141 schema:familyName Li
142 schema:givenName G. D.
143 rdf:type schema:Person
144 N416465ef1ee0481e8294659de96def33 rdf:first N6793b0e3750a4f3e825b42791ad25aae
145 rdf:rest N3a306ec29eba4f0b81b2fbfa473603f5
146 N418837322ed543f48e693ab1aabb3ff8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Survival Analysis
148 rdf:type schema:DefinedTerm
149 N5a8ca6c4437e447b813b6fbfcf784011 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prognosis
151 rdf:type schema:DefinedTerm
152 N5c0f684c8f8b4676883e4571d6094964 rdf:first N050760c404aa41cb88386514ef8c1be8
153 rdf:rest N71d90284d59b44be8c3b88a852e7597f
154 N6793b0e3750a4f3e825b42791ad25aae schema:affiliation grid-institutes:grid.452404.3
155 schema:familyName Wei
156 schema:givenName N.
157 rdf:type schema:Person
158 N67c53674987f4a669271b7f298e68928 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Female
160 rdf:type schema:DefinedTerm
161 N6fcd41767e334c709771dd311a117a48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Thiophenes
163 rdf:type schema:DefinedTerm
164 N71d90284d59b44be8c3b88a852e7597f rdf:first N127a085f86134935a8eee6bd33aed6da
165 rdf:rest rdf:nil
166 N763cfcc8c38c42228521963148f5d385 schema:affiliation grid-institutes:grid.410638.8
167 schema:familyName Zhang
168 schema:givenName B.
169 rdf:type schema:Person
170 N7c00322ce07b46f88e186dc4f828c642 schema:issueNumber 4
171 rdf:type schema:PublicationIssue
172 N7cda6460b00b4beca8314c4ceed9fe50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Treatment Outcome
174 rdf:type schema:DefinedTerm
175 N8692b0f89fe84a92b8a7b13464a84005 schema:affiliation grid-institutes:grid.452404.3
176 schema:familyName Wang
177 schema:givenName G. Z.
178 rdf:type schema:Person
179 N8f0ca03ed3254ffd918762fc51b53a75 schema:affiliation grid-institutes:grid.452404.3
180 schema:familyName Wang
181 schema:givenName Y. H.
182 rdf:type schema:Person
183 N95c22bf5961d4398b36a8a5ca4a9835e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Quinazolines
185 rdf:type schema:DefinedTerm
186 N9944d0063ac94db291733941ba925373 schema:name pubmed_id
187 schema:value 30306400
188 rdf:type schema:PropertyValue
189 N9a6c1927454a46c497690bf003b1b311 schema:affiliation grid-institutes:grid.452404.3
190 schema:familyName He
191 schema:givenName X. H.
192 rdf:type schema:Person
193 N9df1b424ba184dd4b3a0e5db09d2cdbd schema:affiliation grid-institutes:grid.452404.3
194 schema:familyName Xu
195 schema:givenName L. C.
196 rdf:type schema:Person
197 Na6555e985d17476fb0dec552013e9b79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Middle Aged
199 rdf:type schema:DefinedTerm
200 Nae7d67e0464e4a6cb62b36de9c83984e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Liver Neoplasms
202 rdf:type schema:DefinedTerm
203 Nb5ffa7e875864bcabb46fe365baae1b5 schema:name doi
204 schema:value 10.1007/s12094-018-1942-0
205 rdf:type schema:PropertyValue
206 Nbfd9d1feac3c465e9b9c3eacf9ded196 rdf:first N9df1b424ba184dd4b3a0e5db09d2cdbd
207 rdf:rest Ncfe44abe5c7c420f9e5a9b778ed9ddbc
208 Nc223b9a11a2147ad91e4e3c41e636f7a schema:affiliation grid-institutes:grid.452404.3
209 schema:familyName Wang
210 schema:givenName Y.
211 rdf:type schema:Person
212 Nc248c2b9b0a84338b3b1c2f8154d9082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Humans
214 rdf:type schema:DefinedTerm
215 Ncf32596edbc449d0accf009fd4aaee2c schema:volumeNumber 21
216 rdf:type schema:PublicationVolume
217 Ncfe44abe5c7c420f9e5a9b778ed9ddbc rdf:first N3c58b7df38df49579afb88176d4ee8b5
218 rdf:rest Ne0be6d93125e44fca081e0c5769ac322
219 Nd53461c0b7d44e63862e578668981113 rdf:first Nc223b9a11a2147ad91e4e3c41e636f7a
220 rdf:rest N26fa7b97ac894aad83dc7d4dc72990a7
221 Ne0be6d93125e44fca081e0c5769ac322 rdf:first N8f0ca03ed3254ffd918762fc51b53a75
222 rdf:rest Nfaa6af4838fb4ab1a5e31910c541db76
223 Ne13faefb94d5494c8c6f84db06068af9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
224 schema:name Antineoplastic Combined Chemotherapy Protocols
225 rdf:type schema:DefinedTerm
226 Ne85b40a9a17c4084a3f0fb9d7b2488e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
227 schema:name Aged
228 rdf:type schema:DefinedTerm
229 Nf5721267517e4e17bfa59c5929974462 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Retrospective Studies
231 rdf:type schema:DefinedTerm
232 Nfaa6af4838fb4ab1a5e31910c541db76 rdf:first N8692b0f89fe84a92b8a7b13464a84005
233 rdf:rest N5c0f684c8f8b4676883e4571d6094964
234 Nfde4c1ca94de437ba92fef9936233839 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Colorectal Neoplasms
236 rdf:type schema:DefinedTerm
237 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
238 schema:name Medical and Health Sciences
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
241 schema:name Oncology and Carcinogenesis
242 rdf:type schema:DefinedTerm
243 sg:journal.1035367 schema:issn 1699-048X
244 1699-3055
245 schema:name Clinical and Translational Oncology
246 schema:publisher Springer Nature
247 rdf:type schema:Periodical
248 sg:pub.10.1007/978-3-642-82635-1_30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009009928
249 https://doi.org/10.1007/978-3-642-82635-1_30
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s00280-014-2585-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015600148
252 https://doi.org/10.1007/s00280-014-2585-7
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s00423-015-1308-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020499797
255 https://doi.org/10.1007/s00423-015-1308-9
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s12094-012-0843-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1029696709
258 https://doi.org/10.1007/s12094-012-0843-x
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/bjc.1994.68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027895860
261 https://doi.org/10.1038/bjc.1994.68
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/sj.bjc.6602860 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018854110
264 https://doi.org/10.1038/sj.bjc.6602860
265 rdf:type schema:CreativeWork
266 sg:pub.10.1245/s10434-008-0043-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013503650
267 https://doi.org/10.1245/s10434-008-0043-7
268 rdf:type schema:CreativeWork
269 sg:pub.10.1385/mo:21:1:59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042837122
270 https://doi.org/10.1385/mo:21:1:59
271 rdf:type schema:CreativeWork
272 grid-institutes:grid.410638.8 schema:alternateName Department of Interventional Medical, Peoples Hospital Xintai City, Taishan Medical University, 271200, Xintai, China
273 schema:name Department of Interventional Medical, Peoples Hospital Xintai City, Taishan Medical University, 271200, Xintai, China
274 rdf:type schema:Organization
275 grid-institutes:grid.452404.3 schema:alternateName Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China
276 schema:name Department of Interventional Radiology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...